Neos Therapeutics (NEOS) Reports Q2 Loss of $1.65/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. GNK
2. SPY
3. NVDA
4. AZN
5. FNGR
6. PLUR
7. HIVE
8. SPCX
9. GSAT
10. S

Go back to Neos Therapeutics (NEOS) Reports Q2 Loss of $1.65/Share

Neos Therapeutics Announces Second Quarter 2016 Financial Results

August 11, 2016 7:01 AM EDT

DALLAS/FORT WORTH, Texas, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced financial results for the second quarter ended June 30, 2016 and provided a business update.

We are pleased with the steady increase in demand for Adzenys XR-ODT since the launch on May 16, 2016. We are receiving positive feedback from both physicians and patients, and adoption across multiple age groups has been encouraging. We anticipate... More